Cover Image
市場調查報告書

去勢療法無效前列腺癌 (CRPC) / HRPCA的全球市場:市場機會及市場預測 2014-2020年

World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020

出版商 Allied Market Research 商品編碼 337018
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
去勢療法無效前列腺癌 (CRPC) / HRPCA的全球市場:市場機會及市場預測 2014-2020年 World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020
出版日期: 2015年07月01日 內容資訊: 英文 122 Pages
簡介

全球去勢療法無效前列腺癌 (CRPC) / 內分泌療法復發性前列腺癌 (HRPCA) 市場,從2015年2020年的期間以9.1%的年複合成長率持續擴大,預計市場規模到2020年達到95億美元。有潛力的藥劑開發平台,治療模式的演進,未開發的非轉移性CRPC領域的新興及患者認識的增加,預計將促進市場成長。再加上亞太地區、LAMEA (南美、中東、非洲) 地區的未開發CRPC市場,在預測期間內也將加速市場整體的成長。另一方面,CRPC藥物的補貼價格設定,不透明的醫療費償付政策及認證藥和新藥之間作用機制缺乏差異化,預計將抑制市場成長。

本報告提供去勢療法無效前列腺癌 (CRPC) / 內分泌療法復發性前列腺癌 (HRPCA) 的全球市場調查、CRPC (轉移性、非轉移性) 市場上現在、新興市場趨勢和動態的詳細分析、治療類型、藥物遞輸手法、各地區的市場分析與預測,及主要企業的簡介等彙整。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義及範圍
  • 變化的HRPC市場情勢
  • 非轉移性CRPC市場展望
  • 轉移性CRPC市場術前、術後化療的狀況
  • Xtandi vs. Zytiga 各11個特性詳細的市場展望調查
  • 主要調查結果
  • 企業與策略的競爭情報
  • 法規、醫療費償付情形
  • 波特的五力分析
  • 市場機會
  • 市場佔有率分析
  • 價值鏈分析 (企業、產品的展望)
  • 專利分析
  • 市場動態

第4章 開發平台概要

  • 調查目的
  • 開發平台的說明
  • 開發平台的分析
  • 調查的意義

第5章 全球CRPC市場:各治療類型

  • 荷爾蒙療法
  • 化療
  • 免疫療法
  • 放射線治療

第6章 全球CRPC市場:各藥物遞輸手法

  • 口腔途徑
    • 主要的市場趨勢
    • 主要的成長要素、機會
    • 市場規模、預測
  • 注射途徑

第7章 全球CRPC市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • LAMEA (南美、中東、非洲)

第8章 企業簡介

  • Johnson & Johnson
    • 公司概要
    • 概述
    • 產業區分概要
    • 財務效能
    • 策略性的動向、發展
    • SWOT分析
  • Dendreon Corporation
  • Sanofi
  • Bayer
  • Astellas Pharma Inc.

圖表清單

目錄

Title: World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market by Therapy Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy) and Drug Delivery Method (Oral Therapy, Injectable Therapy) - Global Opportunity Analysis and Industry Forecast, 2014 - 2020.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

The global CRPC market is expected to reach $9.5 billion by 2020, at a CAGR of 9.1% during the forecast period (2015-2020). Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.

The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.

To provide a detailed market assessment, the report segments the CRPC market on the basis of therapy type, drug delivery method and geography. Based on therapy type, the market is segmented across various segments such as Chemotherapy, Hormonal Therapy, Immunotherapy and Radiotherapy. Hormonal therapy segment spearheads the therapy types market, governing around 4/5th of the global market value in 2014 and would continue to maintain its market position during the forecast period (2015-2020). Radiation therapy segment is projected as the fastest growing segment throughout the forecast period. Based on drug delivery method, the market is segmented into oral and injectable therapy segments. Oral therapy segment dominates the global CRPC market; however, injectable segment is expected to grow at a faster rate. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific and LAMEA regions. North America region governs a dominant share in the global CRPC market; however, Asia-Pacific and LAMEA region are expected to register the highest CAGR during the forecast period.

The market registered substantial growth in the recent years, owing to the various strategies adopted by leading market players. One of the key strategies adopted is collaboration agreement. Astellas Pharma Inc. for instance in 2009, entered into an agreement with Medivation, Inc. to co-develop and co-commercialize MDV3100 (now Xtandi) for the treatment of CRPC. A comprehensive competitive analysis and profiles of major market players such as Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others have been provided in the report.

KEY MARKET BENEFITS:

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global CRPC (metastatic and non-metastatic) market
  • The CRPC market scenario is comprehensively analysed in accordance to the key regions
  • In-depth analysis of CRPC (chemotherapy and post-chemo) settings is implemented in the report
  • The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014-2020
  • Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used therapy drugs and evolving role of immunotherapies and radiopharmaceuticals
  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
  • Owing to an emerging pipeline in the market, pipeline analysis studies have also been taken into account to better understand the market potential and opportunities
  • Competitive intelligence highlights the business practises followed by leading market players across geographies

KEY MARKET SEGMENTS:

The Global CRPC market segmentation is illustrated below:

  • Global CRPC Market By Therapy Type
    • Chemotherapy
      • Cytotoxic Agents
    • Hormonal Therapy
      • Anti-Androgens
    • Immunotherapy
      • Vaccines
    • Radiotherapy
      • Radio-Pharmaceuticals
  • Global CRPC Market By Drug Delivery Method
    • Oral Therapy
    • Injectable Therapy
  • Global CRPC Market By Geography
    • North America
    • Europe
    • Asia-Pacific
    • LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. KeyBenefits
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective
  • 2.2. Market Beyond: What to Expect by 2025
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Changing Landscape of HRPC Market
  • 3.3. Non-Metastatic CRPC Market Perspective
  • 3.4. Metastatic CRPC Market Pre-Chemo and Post-Chemo Settings
  • 3.5. Xtandi vs. Zytiga Detailed Market Outlook Study of 11 Different Attributes
  • 3.6. Key Findings
    • 3.6.1. Top impacting factors
    • 3.6.2. Top investment pockets
    • 3.6.3. Topwinning strategies
  • 3.7. Competitive Intelligence of companies and their strategies
  • 3.8. Regulations and Reimbursement Scenario
  • 3.9. Porters Five Forces Analysis
    • 3.9.1. High competition and fragmented nature reduces the power of the suppliers
    • 3.9.2. Scattered nature and large number of buyers moderates the power of the buyers
    • 3.9.3. Intense competition among existing rivalry
    • 3.9.4. High initial cost lowers the threat of new entrants
    • 3.9.5. Unavailability of substitutes moderates the threat of substitutes
    • 3.9.6. Imperative deductions about the CRPC market
  • 3.10. Market Opportunity
    • 3.10.1. Lucrative opportunities in emerging markets
    • 3.10.2. Untapped Non-Metastatic CRPC (nmCRPC) market opportunity
  • 3.11. Market Share Analysis, 2014
  • 3.12. Value Chain Analysis (Company and Product Perspective)
    • 3.12.1. Value chainanalysis by companies
      • 3.12.1.1. Developer analysis
      • 3.12.1.2. Manufacturer analysis
      • 3.12.1.3. Marketer analysis
      • 3.12.1.4. Distributor analysis
      • 3.12.1.5. Key Takeaways
    • 3.12.2. Value chain analysis by products
  • 3.13. Patent Analysis
  • 3.14. MarketDynamics
    • 3.14.1. Drivers
      • 3.14.1.1. Rising incidence and high mortality of prostate cancer worldwide
      • 3.14.1.2. Limited treatment options and high unmet need for ideal treatment
      • 3.14.1.3. Strong emerging pipeline and in-line extensions (ILE) opted for existing therapies
      • 3.14.1.4. Growing awareness leading to increased diagnosis
    • 3.14.2. Restraints
      • 3.14.2.1. Limited reimbursement and coverage by payers
      • 3.14.2.2. High costsdue to combination therapies
      • 3.14.2.3. Limited survival periods

CHAPTER 4: PIPELINE OVERVIEW

  • 4.1. Study Objectives
  • 4.2. Pipeline Description
  • 4.3. Pipeline Analysis
    • 4.3.1. Drugsin pipeline
    • 4.3.2. Trials according to primary completion year
    • 4.3.3. NMEs and ILEs in CRPC
    • 4.3.4. Companies in CRPC
    • 4.3.5. Failure rates in CRPC
  • 4.4. Study Implications

CHAPTER 5: GLOBAL CRPC MARKET BY THERAPY TYPE

  • 5.1. HormonalTherapy
    • 5.1.1. Historical milestones
    • 5.1.2. Hormonal therapy product-wise market size and forecast
    • 5.1.3. Key market trends
    • 5.1.4. Key growth factors and opportunities
    • 5.1.5. Market size and forecast
  • 5.2. Chemotherapy
    • 5.2.1. Historical milestones
    • 5.2.2. Chemotherapy product-wise market size and forecast
    • 5.2.3. Key market trends
    • 5.2.4. Key growth factors and opportunities
    • 5.2.5. Market size and forecast
  • 5.3. Immunotherapy
    • 5.3.1. Historical milestones
    • 5.3.2. Immunotherapy product-wise market size and forecast
    • 5.3.3. Key market trends
    • 5.3.4. Key growth factors and opportunities
    • 5.3.5. Market size and forecast
  • 5.4. Radiotherapy
    • 5.4.1. Historical milestones
    • 5.4.2. Radiotherapy product-wise market size and forecast
    • 5.4.3. Key market trends
    • 5.4.4. Key growth factors and opportunities
    • 5.4.5. Market size and forecast

CHAPTER 6: GLOBAL CRPC MARKET BY DRUG DELIVERY METHOD

  • 6.1. Oral Route
    • 6.1.1. Key market trends
    • 6.1.2. Key growth factors and opportunities
    • 6.1.3. Market size and forecast
  • 6.2. Injectable route
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast

CHAPTER 7: GLOBAL CRPC MARKET BY GEOGRAPHY

  • 7.1. NorthAmerica
    • 7.1.1. Key market trends
    • 7.1.2. Key growth factors and opportunities
    • 7.1.3. Market size and forecast
  • 7.2. Europe
    • 7.2.1. Key market trends
    • 7.2.2. Keygrowth factors and opportunities
    • 7.2.3. Market size and forecast
  • 7.3. Asia-Pacific
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast
  • 7.4. LAMEA
    • 7.4.1. Keymarket trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast

CHAPTER 8: COMPANY PROFILES

  • 8.1. Johnson & Johnson
    • 8.1.1. Company Overview
    • 8.1.2. Johnson & Johnson Snapshot
    • 8.1.3. Operating Business Segment Overview
    • 8.1.4. Financial performance
    • 8.1.5. Strategic moves and developments
      • 8.1.5.1. PRINCIPAL STRATEGIES: PRODUCT LAUNCH
      • 8.1.5.2. SECONDARY STRATEGIES: APPROVALS
      • 8.1.5.3. OTHER STRATEGIES: ACQUISITIONS
    • 8.1.6. SWOT analysis and strategic deductions
  • 8.2. Dendreon Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Dendreon Corporation Snapshot
    • 8.2.3. Operating Business Segment Overview
    • 8.2.4. Financial performance
    • 8.2.5. Strategic moves and developments
    • 8.2.6. SWOT analysis and strategic deductions
  • 8.3. Sanofi
    • 8.3.1. Company Overview
    • 8.3.2. Sanofi Snapshot
    • 8.3.3. Operating Business Segment Overview
    • 8.3.4. Financial performance
    • 8.3.5. Strategic moves and developments
    • 8.3.6. SWOT analysis and strategic deductions
  • 8.4. Bayer
    • 8.4.1. Company Overview
    • 8.4.2. Bayer Snapshot
    • 8.4.3. Operating Business Segment Overview
    • 8.4.4. Financial performance
    • 8.4.5. Strategic moves and developments
    • 8.4.6. SWOT analysis and strategic deductions
  • 8.5. Astellas Pharma Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Astellas Snapshot
    • 8.5.3. Operating Business Segment Overview
    • 8.5.4. Financial performance
    • 8.5.5. Strategic moves and developments
    • 8.5.6. SWOT analysis and strategic deductions

List of Tables

  • TABLE 1: GLOBAL CRPC MARKET,MODERATE GROWTH SCENARIO, BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 2: GLOBAL CRPC MARKET, RAPID GROWTH SCENARIO, BY GEOGRAPHY, 2020-2025, ($MILLION)
  • TABLE 3: GLOBAL CRPC MARKET, DIMINISHING GROWTH SCENARIO, BY GEOGRAPHY, 2020-2025, ($MILLION)
  • TABLE 4: CLINICAL AND NON-CLINICAL ATTRIBUTES OF XTANDI AND ZYTIGA
  • TABLE 5: REIMBURSEMENT PATTERN OF CRPC DRUGS
  • TABLE 6: COMPETITIVE INTELLIGENCE OF DRUG INNOVATORS
  • TABLE 7: REIMBURSEMENT PATTERN OF CRPC DRUGS
  • TABLE 8: MARKET SHARE AND REVENUE OF CRPC DRUG INNOVATORS
  • TABLE 9: LOOMING OFF-PATENTS OF CRPC DRUGS
  • TABLE 10: FDA APPROVED TREATMENTS FOR CPRC AND THEIR SURVIVAL BENEFITS
  • TABLE 11: EMERGING PIPELINE AND IN-LINE EXTENSIONS FOR CPRC
  • TABLE 12: REIMBURSEMENT AND FDA APPROVAL FOR CPRC DRUGS
  • TABLE 13: PIPELINE FOR CPRC DRUGS
  • TABLE 14: GLOBAL CRPC MARKET, BY THERAPY TYPES, 2014-2020, ($MILLION)
  • TABLE 15: HORMONAL THERAPY DRUGS AND THEIR REVENUES IN 2014
  • TABLE 16: GLOBAL HORMONAL THERAPY PRODUCTS MARKET, BY TYPE, 2014-2020, ($MILLION)
  • TABLE 17: GLOBAL HORMONAL THERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 18: CHEMOTHERAPY DRUGS AND THEIR REVENUES IN 2014
  • TABLE 19: GLOBAL CHEMOTHERAPY DRUG MARKET, BY TYPE, 2014-2020, ($MILLION)
  • TABLE 20: GLOBAL CHEMOTHERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 21: IMMUNOTHERAPY DRUGS AND THEIR REVENUES IN 2014
  • TABLE 22: GLOBAL IMMUNOTHERAPY DRUG MARKET, BY TYPE, 2014-2020, ($MILLION)
  • TABLE 23: GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 24: RADIOTHERAPY DRUGS AND THEIR REVENUES IN 2014
  • TABLE 25: GLOBAL RADIOTHERAPY DRUG MARKET, BY TYPE, 2014-2020, ($MILLION)
  • TABLE 26: GLOBAL RADIOTHERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 27: GLOBAL ORAL THERAPY MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 28: GLOBAL INJECTABLE THERAPY MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 29: GLOBAL CRPC MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
  • TABLE 30: CRPC TREATMENTS APPROVED IN UNITED STATES
  • TABLE 31: NORTH AMERICA CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
  • TABLE 32: HIGH INCIDENCE RATES AT DIAGNOSIS IN EU-5 NATIONS AS COMPARED TO UNITED STATES
  • TABLE 33: EUROPE CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
  • TABLE 34: CRPC TREATMENTS AVAILABLE AND CONSIDERATION FACTORS IN ASIA PACIFIC REGION
  • TABLE 35: HIGH INCIDENCE RATES AT DIAGNOSIS IN ASIA PACIFIC REGION RESULT OF LOW PSA SCREENING
  • TABLE 36: ASIA PACIFIC CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
  • TABLE 37: INCIDENCE AND DEATHS FROM PROSTATE CANCER IN LATIN AMERICA
  • TABLE 38: LAMEA CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
  • TABLE 39: COMPANY SNAPSHOT OF JOHNSON & JOHSNON
  • TABLE 40: JOHNSON & JOHSNON OPERATING SEGMENTS
  • TABLE 41: COMPANY SNAPSHOT OF DENDREON CORPORATION
  • TABLE 42: DENDREON CORPORATION OPERATING SEGMENTS
  • TABLE 43: COMPANY SNAPSHOT OF SANOFI
  • TABLE 44: SANOFI OPERATING SEGMENTS
  • TABLE 45: COMPANY SNAPSHOT OF BAYER
  • TABLE 46: BAYER OPERATING SEGMENTS
  • TABLE 47: COMPANY SNAPSHOT OF ASTELLAS
  • TABLE 48: ASTELLAS OPERATING SEGMENTS

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF GLOBAL CRPC MARKET IN MODERATE GROWTH SCENARIO
  • FIG. 2: IMPACT ANALYSIS OF GLOBAL CRPC MARKET IN RAPID GROWTH SCENARIO
  • FIG. 3: IMPACT ANALYSIS OF GLOBAL CRPC MARKET IN DIMINISHING GROWTH SCENARIO
  • FIG. 4: GLOBAL HORMONE REFRACTORY PROSTATE CANCER (HRPCA) MARKET DEFINITION
  • FIG. 5: EVOLUTION OF CRPC TREATMENT REGIME
  • FIG. 6: NON-METASTATIC CRPC MARKET PERSPECTIVE
  • FIG. 7: PRE-CHEMO AND POST-CHEMO CRPC MARKET POTENTIAL
  • FIG. 8: DETAILED MARKET OUTLOOK OF XTANDI VS. ZYTIGA
  • FIG. 9: TOP IMPACTING FACTORS
  • FIG. 10: TOP INVESTMENT POCKETS
  • FIG. 11: TOP WINNING STRATEGIES PERCENTAGE DISTRIBUTION
  • FIG. 12: TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIG. 13: TYPES OF STRATEGIES DISTRIBUTION
  • FIG. 14: TOP COMPANIES AND THEIR STRATEGIES
  • FIG. 15: DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
  • FIG. 16: DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
  • FIG. 17: PORTERS FIVE FORCE ANALYSIS
  • FIG. 18: MARKET SHARE ANALYSIS (2014)
  • FIG. 19: VALUE CHAIN ANALYSIS BY COMPANIES
  • FIG. 20: VALUE CHAIN ANALYSIS BY PRODUCT
  • FIG. 21: MANUFACTURING PROCESS OF ZYTIGA
  • FIG. 22: MARKET DYNAMICS SNAPSHOT
  • FIG. 23: AVERAGE NUMBER OF DEATHS PER YEAR AND AGE-SPECIFIC MORTALITY RATES PER 100,000 POPULATION, UK (2010-2012)
  • FIG. 24: DRUGS IN PIPELINE
  • FIG. 25: TRIALS ACCORDING TO PRIMARY COMPLETION YEAR
  • FIG. 26: NMES AND ILES IN CRPC
  • FIG. 27: COMPANIES IN CRPC
  • FIG. 28: FAILURE RATES IN CRPC
  • FIG. 29: KEY FINANCIALS OF JOHNSON & JOHSNON $ MILLION (2012-2014)
  • FIG. 30: FINANCIAL REVENUES BY SEGMENTS (2014)
  • FIG. 31: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 32: SWOT ANALYSIS OF JOHNSON & JOHSNON
  • FIG. 33: KEY FINANCIALS OF DENDREON CORPORATION $ THOUSANDS (2011-2013)
  • FIG. 34: FINANCIAL REVENUES BY GEOGRAPHY (2013)
  • FIG. 35: SWOT ANALYSIS OF DENDREON CORPORATION
  • FIG. 36: KEY FINANCIALS OF BAYER $ MILLIONS (2012-2014)
  • FIG. 37: FINANCIAL REVENUES BY SEGMENTS (2014)
  • FIG. 38: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 39: SWOT ANALYSIS OF SANOFI
  • FIG. 40: KEY FINANCIALS OF BAYER $ MILLIONS (2012-2014)
  • FIG. 41: FINANCIAL REVENUES BY SEGMENTS (2014)
  • FIG. 42: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 43: SWOT ANALYSIS OF BAYER
  • FIG. 44: KEY FINANCIALS OF ASTELLAS $ MILLIONS (2012-2013)
  • FIG. 45: FINANCIAL REVENUES BY GEOGRAPHY (2013)
  • FIG. 46: SWOT ANALYSIS OF ASTELLAS
Back to Top